The news: OpenAI acquired Orchestra Bio⁠, an AI-powered platform that helps pharma and biotech firms advance drug development programs. Terms of the deal were not disclosed.

OpenAI’s life sciences AI model, Rosalind, will work alongside Orchestra to accelerate scientific discovery and speed time to market.

• Rosalind helps scientists tackle biology and chemistry questions, analyze data, and plan experiments using scientific tools.
• Orchestra creates AI agents that streamline drug-discovery operations such as clinical trial scheduling and monitoring complex laboratory studies.

Why it matters: OpenAI’s previous pharma and life sciences efforts centered on partnerships with drugmakers like Novo Nordisk, Sanofi, and Moderna to accelerate R&D and streamline operations. This marks its first known acquisition in the space. The strategy follows rival Anthropic, which launched its pharma- and life sciences-focused Claude Science platform in June alongside plans to explore in-house drug development, in addition to acquiring biotech AI startup Coefficient Bio in April.

AI companies recognize deep-pocketed pharma companies as lucrative potential customers looking to address high costs, lengthy timelines, and clinical trial failure rates in drug discovery:

• OpenAI noted that developing a new medicine is extremely complex, taking roughly 10 to 15 years on average from target discovery to regulatory approval in the US.
• Pharma executives are bullish on AI’s potential to reduce the industry’s ~90% trial failure rate by improving patient selection, trial design, and early predictions of toxicity or lack of efficacy.
• AI could also lower drug discovery costs by using digital simulations and data analysis to reduce reliance on costly, time-consuming lab experiments.

Implications for pharma and AI companies: Pharma companies are enthusiastic about the potential of AI. We see that in surging spending on drug discovery partnerships and licensing deals, which will continue to drive AI giants and specialized drug discovery tech firms to embed AI deeper into R&D workflows. Smaller AI startups may also seek acquisitions to capitalize on strong market interest before pressure to demonstrate tangible clinical and financial returns dampens enthusiasm and valuations. That pressure could intensify as AI’s impact on clinical outcomes and development costs remains limited to date. For now, ambitious predictions of shrinking drug discovery timelines from years to months are helping AI companies position themselves to capture more pharma investment.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.